JP2024510267A - 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法 - Google Patents

線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法 Download PDF

Info

Publication number
JP2024510267A
JP2024510267A JP2023556985A JP2023556985A JP2024510267A JP 2024510267 A JP2024510267 A JP 2024510267A JP 2023556985 A JP2023556985 A JP 2023556985A JP 2023556985 A JP2023556985 A JP 2023556985A JP 2024510267 A JP2024510267 A JP 2024510267A
Authority
JP
Japan
Prior art keywords
isotope
compound according
radiotherapy
magnetic resonance
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510267A5 (https=
JPWO2022197567A5 (https=
Inventor
ロウ，フィリップ，スチュワート
ムッカマラ，ラメシュ
スリニヴァサラオ，マッドゥリ
リンデマン，スペンサー，ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2024510267A publication Critical patent/JP2024510267A/ja
Publication of JP2024510267A5 publication Critical patent/JP2024510267A5/ja
Publication of JPWO2022197567A5 publication Critical patent/JPWO2022197567A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023556985A 2021-03-16 2022-03-12 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法 Pending JP2024510267A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163200592P 2021-03-16 2021-03-16
US202163161835P 2021-03-16 2021-03-16
US202163200593P 2021-03-16 2021-03-16
US63/161,835 2021-03-16
US63/200,593 2021-03-16
US63/200,592 2021-03-16
US202163165563P 2021-03-24 2021-03-24
US202163165583P 2021-03-24 2021-03-24
US202163165550P 2021-03-24 2021-03-24
US63/165,563 2021-03-24
US63/165,550 2021-03-24
US63/165,583 2021-03-24
PCT/US2022/020084 WO2022197567A1 (en) 2021-03-16 2022-03-12 Compounds targeting fibroblast-activation protein and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024510267A true JP2024510267A (ja) 2024-03-06
JP2024510267A5 JP2024510267A5 (https=) 2025-03-21
JPWO2022197567A5 JPWO2022197567A5 (https=) 2025-03-21

Family

ID=83320754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556985A Pending JP2024510267A (ja) 2021-03-16 2022-03-12 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法

Country Status (6)

Country Link
US (1) US20240238458A1 (https=)
EP (1) EP4308110A4 (https=)
JP (1) JP2024510267A (https=)
CA (1) CA3212210A1 (https=)
TW (1) TW202300143A (https=)
WO (1) WO2022197567A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879182B (zh) * 2023-10-26 2025-04-01 國家原子能科技研究院 白蛋白雙重結合功能之纖維母細胞活化蛋白化合物或其鹽
WO2025155818A1 (en) * 2024-01-19 2025-07-24 Purdue Research Foundation Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators
WO2025171343A1 (en) * 2024-02-08 2025-08-14 Immunome, Inc. Compounds targeting fibroblast-activation protein and methods of use thereof
CN118593732B (zh) * 2024-06-27 2025-03-11 华中科技大学同济医学院附属同济医院 一种心肌炎核素分子探针及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) * 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
WO2019190266A1 (ko) * 2018-03-30 2019-10-03 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
JP2020502130A (ja) * 2016-12-14 2020-01-23 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2020081522A1 (en) * 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
WO2020205948A1 (en) * 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1943257A2 (en) * 2005-05-19 2008-07-16 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
JP6744826B2 (ja) * 2014-06-13 2020-08-19 バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC Ｆａｐ活性化治療剤及びそれに関連する使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) * 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
JP2020502130A (ja) * 2016-12-14 2020-01-23 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2019190266A1 (ko) * 2018-03-30 2019-10-03 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
WO2020081522A1 (en) * 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
WO2020205948A1 (en) * 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSAI, TING-YUEH 他: "Substituted 4-Carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibrobla", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53(18), JPN6025052720, 2010, pages 6572 - 6583, ISSN: 0005760281 *

Also Published As

Publication number Publication date
US20240238458A1 (en) 2024-07-18
EP4308110A4 (en) 2025-06-18
WO2022197567A1 (en) 2022-09-22
EP4308110A1 (en) 2024-01-24
TW202300143A (zh) 2023-01-01
CA3212210A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP2024510267A (ja) 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法
AU2020348781B2 (en) Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
ES3044433T3 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
EP4003321A1 (en) Multivalent fibroblast-targeted agents and methods of use
KR102187940B1 (ko) 트리아진계 방사성 의약품 및 방사성 이미지화제
KR20090108086A (ko) 췌장암 치료용 조성물
US20240342318A1 (en) Conjugates comprising covalent binders for targeting intracellular proteins
WO2021083328A1 (zh) 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
TW202346293A (zh) 含氮雜環衍生物及其组合物和藥學上的應用
US20250025582A1 (en) Ligands and their use
KR102168738B1 (ko) 히단토인 유도체
AU2020360970B2 (en) Prostaglandin E2 (PGE2) EP4 receptor antagonists
CN117460507A (zh) 靶向成纤维细胞激活蛋白的化合物及其使用方法
JP2022514685A (ja) ペンタミジンの類似体及びその使用
CN114072402B (zh) 作为fgfr和vegfr双重抑制剂的吡啶衍生物
EA051572B1 (ru) Фибробласт-активирующий белок (far)-таргетированная визуализация и терапия злокачественных опухолей и других фиброзирующих и воспалительных заболеваний
JP2022521715A (ja) がん治療のためのｆｇｆｒ阻害剤
JP2025518731A (ja) ４－（３ｈ－ピラゾロ［４，３－ｆ］キノリン－７－イル）－ｎ－（２－（ジメチルアミノ）エチル）ベンズアミド－またはヒドロキサム酸化合物、組成物、および使用の方法
CN118894812A (zh) 一类化合物及其制备方法和医药用途
JP2026514055A (ja) Ｅｒｂｂ２阻害薬
HK40072758A (en) Multivalent fibroblast-targeted agents and methods of use
HK1212908B (zh) 三嗪类放射性药物和放射性显影剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414